[Haloperidol decanoate: results of a 6-month open trial in paranoid schizophrenia].
An open clinical trial with Haloperidol Decanoate was carried out in order to determine its therapeutic efficacy, side effects, and tolerance. The sample population was a 30 male-and-female-psychotic-patient group (15 in-patients and 15 out-patients treated at a private psychiatric institution). A marked stabilizing effect with no relapses was observed. Therefore, it can safely be said that Haloperidol Decanoate helped in controling these patients satisfactorily, and getting a positive social reintegration.
Pérez
C
C
Clínica Privada Gregorio Marañón, Castelar, Argentina.
Stier Rosner
S E
SE
D000328:Adult; D001519:Behavior / Q000187:drug effects*; D010054:Brief Psychiatric Rating Scale; D002986:Clinical Trials as Topic; D004361:Drug Tolerance; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D012563:Schizophrenia, Paranoid / Q000188:drug therapy*; D012565:Schizophrenic Psychology
C033563:haloperidol decanoate; D006220:Haloperidol
Haloperidol decanoato: resultados de un ensayo abierto de 6 meses de duración en esquizofrenia paranoide.